{"id":"NCT02105662","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"An Efficacy and Safety Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in the Treatment of Chronic Hepatitis C Virus in Participants Who Are Co-Infected With Human Immunodeficiency Virus:C-EDGE CO-INFXN (MK-5172-061)","officialTitle":"A Phase III Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen Grazoprevir (GZR) and Elbasvir (EBR) in Treatment-Na√Øve Subjects With Chronic HCV GT1, GT4, and GT6 Infection Who Are Co-Infected With HIV","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-06-03","primaryCompletion":"2015-02-20","completion":"2015-05-22","firstPosted":"2014-04-07","resultsPosted":"2016-03-04","lastUpdate":"2021-02-05"},"enrollment":218,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Hepatitis C"],"interventions":[{"type":"DRUG","name":"Grazoprevir 100 mg/Elbasvir 50 mg fixed-dose combination tablets","otherNames":["MK-5172A"]}],"arms":[{"label":"Grazoprevir+Elbasvir","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to assess the efficacy and safety of grazoprevir (MK-5172) 100 mg in combination with elbasvir (MK-8742) 50 mg in the treatment of chronic hepatitis C virus (HCV) in participants who are co-infected with human immunodeficiency virus (HIV). The primary hypothesis is that the percentage of participants who receive grazoprevir + elbasvir and achieve Sustained Virologic Response after 12 weeks of therapy (SVR12) will be greater than 70%.","primaryOutcome":{"measure":"Percentage of Participants Achieving Sustained Virologic Response 12 Weeks After the End of All Study Therapy (SVR12)","timeFrame":"12 weeks after end of all therapy (Study Week 24)","effectByArm":[{"arm":"Grazoprevir+Elbasvir","deltaMin":96.3,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":13},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["26423374","29461687","29404492","28193518"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":218},"commonTop":["Fatigue","Headache","Nausea","Diarrhoea","Upper respiratory tract infection"]}}